Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer?

Annals of Nuclear Medicine

Volumn 27, Issue 8, 2013, Pages 756-763

  Akkas, Burcu Esen ^a   Demirel, Busra Bedriye ^a   Dizman, Aysen ^a   Vural, Gulin Ucmak ^a  

^a Ankara Oncology Research and Training Hospital   (Turkey)

Author keywords

Cervical cancer; Metabolic tumor volume; PET CT; Prognosis; SUVmax; Total lesion glycolysis

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EXAMINATION; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE MARKER; DRUG UPTAKE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GLYCOLYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PELVIS; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84886384538     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-013-0745-1     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. WHO/ICO Information Center of HPV and Cervical Cancer (HPV Information Center). Human papillomavirus and related cancers in the world. Summary report 2010. http://www.who.int/hpvcentre/en/.
3. Narayan K, Fisher R, Bernshaw D. Significance of tumor volume and corpus uteri invasion in cervical cancer patients treated by radiotherapy. Int J Gynecol Cancer. 2006;16:623-30.
4. Kim H, Kim W, Lee M, Song E, Loh JJK. Tumor volume and uterine body invasion assessed by MRI for prediction of outcome in cervical carcinoma treated with concurrent chemotherapy and radiotherapy. Jpn J Clin Oncol. 2007;37:858-66.
5. Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park NH, et al. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol. 2011;120:270-4.
6. Burghardt E, Hofmann HM, Ebner F, Haas J, Tamussino K, Justich E. Magnetic resonance imaging in cervical cancer: a basis for objective classification. Gynecol Oncol. 1989;33:61-7.
7. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22:872-80.
8. Jacobs AJ, Faris C, Perez CA, Kao MS, Galakatos A, Camel HM. Short-term persistence of carcinoma of the uterine cervix after radiation. An indicator of long-term prognosis. Cancer. 1986;57:944-50.
9. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110:1738-44.
10. Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol. 2010;28:2108-13.
11. Akkas BE, Demirel BB, Vural GU. Clinical impact of FDG PET/CT in the pretreatment evaluation of patients with locally advanced cervical carcinoma. Nucl Med Commun. 2012;33:1081-8.
12. Choi HJ, Roh JW, Seo SS, Lee S, Kim JY, Kim SK, et al. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study. Cancer. 2006;106:914-22.
13. Son H, Kositwattanarerk A, Hayes MP, Chuang L, Rahaman J, Heiba S, et al. PET/CT evaluation of cervical cancer: spectrum of disease. Radiographics. 2010;30:1251-68.
14. Yoo J, Choi JY, Moon SH, Bae DS, Park SB, Choe YS, Lee KH, Kim BT. Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography. Int J Gynecol Cancer. 2012;22:1226-33.
15. Yen TC, See LC, Lai CH, Tsai CS, Chao A, Hsueh S, Hong JH, Chang TC, Ng KK. Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer. Eur J Nucl Med Mol Imaging. 2008;35:493-501.
16. Kidd EA, El Naqa I, Siegel BA, Dehdashti F, Grigsby PW. FDG-PET-based prognostic nomograms for locally advanced cervical cancer. Gynecol Oncol. 2012;127:136-40.
17. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201-6.
18. Schwartz DL, Rajendran J, Yueh B, Coltrera MD, Leblanc M, Eary J, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg. 2004;130:1361-7.
19. Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg. 2008;33:819-23.
20. Nair VS, Barnett PG, Ananth L, Gould MK. Veterans affairs solitary nodule accuracy project cooperative studies group PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer. Chest. 2010;137:1150-6.
21. Nakamura K, Okumura Y, Kodama J, Hongo A, Kanazawa S, Hiramatsu Y. The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix. Gynecol Oncol. 2010;119:81-6.
22. Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:328-33.
23. Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, et al. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861-8.
24. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non- small cell lung cancer. Radiology. 2012;264:559-66.
25. Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, Wong R, Fury M, Schoder H. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53:1506-13.
26. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53:353-9.
27. Geworski L, Knoop BO, Cabrejas ML, Knapp WH, Munz DL. Recovery correction for quantitation in emission tomography: a feasibility study. Eur J Nucl Med. 2000;27:161-9.
28. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: cervical cancer, 06/02/09 update. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
29. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103-4.
30. Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Post therapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004;22:2167-71.
31. Petignat P, Loubeyre P. Should we modify the current FIGO staging system for early-stage cervical cancer? Expert Rev Anticancer Ther. 2008;8:1015-7.
32. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer. 2010;116:1469-75.
33. Berman ML, Keys H, Creasman W, DiSaia P, Bundy B, Blessing J. Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study). Gynecol Oncol. 1984;19:8-16.
34. Heller PB, Maletano JH, Bundy BN, Barnhill DR, Okagaki T. Clinical-pathologic study of stage IIB, III, and IVA carcinoma of the cervix: extended diagnostic evaluation for paraaortic node metastasis - a Gynecologic Oncology Group study. Gynecol Oncol. 1990;38:425-30.
35. Varia MA, Bundy BN, Deppe G, Mannel R, Averette HE, Rose PG, et al. Cervical carcinoma metastatic to paraaortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1998;42:1015-23.
36. Kang S, Kim SK, Chung DC, Seo SS, Kim JY, Nam BH, et al. Diagnostic value of (18)F-FDG PET for evaluation of paraaortic nodal metastasis in patients with cervical carcinoma: a metaanalysis. J Nucl Med. 2010;51:360-7.
37. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of post therapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA. 2007;298:2289-95.
38. Jacobs AJ, Faris C, Perez CA, Kao MS, Galakatos A, Camel HM. Short-term persistence of carcinoma of the uterine cervix after radiation. An indicator of long-term prognosis. Cancer. 1986;57:944-50.
39. Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med. 2009;50(Suppl 1):64S-73S.
40. Lin LL, Yang Z, Mutic S, Miller TR, Grigsby PW. FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer. Int J Radiat Oncol Biol Phys. 2006;65:177-81.